# Pacira BioSciences (PCRX): Viatris to buy it for $1.65B in cash

> Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, a ~44.8% premium to its last close. Pacira's non-opioid pain drugs Exparel and…

- URL: https://centiview.com/post/pacira-biosciences-pcra-viatris-to-buy-pacira-for-1-65b-in-cash
- Published: 2026-10-13T17:10:00.000Z
- Sectors: Healthcare
- Region: US
- Ticker: PCRX
- Sentiment (opinion, not a recommendation): bullish
- Publisher: Centiview (Persie Ltd, London)
- General information only, not financial advice

Viatris agreed to buy Pacira for $36.50 a share in cash, about $1.65B, a ~44.8% premium to its last close. Pacira's non-opioid pain drugs Exparel and Zilretta bring ~$746M of trailing revenue. Close targeted by end-2026 via tender offer.

> **Why it matters** Viatris is paying up for a non-opioid pain franchise with about $177M of adjusted EBITDA. Shareholders get a clear cash exit, but the deal still needs a majority tender and regulatory clearance.

> **What we verified** Pacira's Oct 8, 2026 8-K confirms $36.50 per share in cash, about $1.65B, a tender offer then merger, and a close expected by end-2026. Reuters (via KSL) matches the terms and reports the 44.8% premium.

### Sources
- [Pacira 8-K press release (SEC)](https://www.sec.gov/Archives/edgar/data/0001396814/000110465926114571/tm2627240d2_ex99-1.htm)
- [Viatris to buy pain therapy maker Pacira BioSciences for $1.65 billion (Reuters via KSL)](https://www.ksl.com/article/51633920/viatris-to-buy-pain-therapy-maker-pacira-biosciences-for-165-billion)